ketoconazole has been researched along with Hyperlipemia in 5 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The target sirolimus area under the concentration curve (AUC) of 3,810 ng-h/mL was achieved at sirolimus doses of 90, 16, and 25 mg in the sirolimus alone, sirolimus plus ketoconazole, and sirolimus plus grapefruit juice studies, respectively." | 2.77 | Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. ( Cohen, EE; Eaton, KN; Fleming, GF; Fox-Kay, K; Gajewski, TF; Hartford, C; House, L; Kocherginsky, M; Maitland, ML; Moshier, K; Nallari, A; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K; Zha, Y, 2012) |
| "BLA = bilateral adrenalectomy CD = Cushing disease CS = Cushing syndrome eCRF = electronic case report form MRI = magnetic resonance imaging PCOS = polycystic ovary syndrome." | 1.46 | BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. ( Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS, 2017) |
| "(±)-Ketoconazole (KTZ) is a chiral antifungal drug that inhibits cytochrome P450 (CYP)-mediated metabolism of other drugs." | 1.37 | The effect of increased lipoprotein levels on the pharmacokinetics of ketoconazole enantiomers in the rat. ( Brocks, DR; Hamdy, DA, 2011) |
| "Hyperlipidemia (HL) was previously shown to lower liver uptake of the more potent (-) enantiomer of ketoconazole (KTZ) in rat." | 1.37 | Effect of hyperlipidemia on ketoconazole-midazolam drug-drug interaction in rat. ( Brocks, DR; Hamdy, DA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geer, EB | 1 |
| Shafiq, I | 1 |
| Gordon, MB | 1 |
| Bonert, V | 1 |
| Ayala, A | 1 |
| Swerdloff, RS | 1 |
| Katznelson, L | 1 |
| Lalazar, Y | 1 |
| Manuylova, E | 1 |
| Pulaski-Liebert, KJ | 1 |
| Carmichael, JD | 1 |
| Hannoush, Z | 1 |
| Surampudi, V | 1 |
| Broder, MS | 1 |
| Cherepanov, D | 1 |
| Eagan, M | 1 |
| Lee, J | 1 |
| Said, Q | 1 |
| Neary, MP | 1 |
| Biller, BMK | 1 |
| Hamdy, DA | 2 |
| Brocks, DR | 2 |
| Cohen, EE | 1 |
| Wu, K | 1 |
| Hartford, C | 1 |
| Kocherginsky, M | 1 |
| Eaton, KN | 1 |
| Zha, Y | 1 |
| Nallari, A | 1 |
| Maitland, ML | 1 |
| Fox-Kay, K | 1 |
| Moshier, K | 1 |
| House, L | 1 |
| Ramirez, J | 1 |
| Undevia, SD | 1 |
| Fleming, GF | 1 |
| Gajewski, TF | 1 |
| Ratain, MJ | 1 |
2 trials available for ketoconazole and Hyperlipemia
| Article | Year |
|---|---|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2012 |
Atorvastatin--a new lipid-lowering drug.
Topics: Anti-Bacterial Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Dose-Response Rela | 1997 |
3 other studies available for ketoconazole and Hyperlipemia
| Article | Year |
|---|---|
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectom | 2017 |
The effect of increased lipoprotein levels on the pharmacokinetics of ketoconazole enantiomers in the rat.
Topics: Animals; Antifungal Agents; Area Under Curve; Hyperlipidemias; Injections, Intravenous; Ketoconazole | 2011 |
Effect of hyperlipidemia on ketoconazole-midazolam drug-drug interaction in rat.
Topics: Animals; Blood Proteins; Drug Interactions; Hyperlipidemias; Ketoconazole; Male; Midazolam; Protein | 2011 |